Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, J.Molner AS's Enterprise Value is €32.40 Mil.
J.Molner AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €0.61 Mil. Therefore, J.Molner AS's EV-to-EBIT ratio for today is 53.02.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, J.Molner AS's Enterprise Value is €32.40 Mil.
J.Molner AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.87 Mil. Therefore, J.Molner AS's EV-to-EBITDA ratio for today is 37.32.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, J.Molner AS's Enterprise Value is €32.40 Mil.
J.Molner AS's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €1.15 Mil. Therefore, J.Molner AS's EV-to-Revenue ratio for today is 28.27.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, J.Molner AS's Enterprise Value is €32.40 Mil.
J.Molner AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.57 Mil. Therefore, J.Molner AS's EV-to-FCF ratio for today is -12.63.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
J.Molner AS (OTSE:MOLNR) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
J.Molner AS's current Enterprise Value is €32.40 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. J.Molner AS's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €0.61 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
J.Molner AS's current Enterprise Value is €32.40 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. J.Molner AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.87 Mil.
J.Molner AS's current Enterprise Value is €32.40 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. J.Molner AS's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €1.15 Mil.
J.Molner AS's current Enterprise Value is €32.40 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. J.Molner AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.51 Mil.
J.Molner AS's current Enterprise Value is €32.40 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. J.Molner AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
J.Molner AS Enterprise Value Related Terms
J.Molner AS Enterprise Value Historical Data
* Premium members only.
The historical data trend for J.Molner AS's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTSE:MOLNR vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J.Molner AS Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's Enterprise Value distribution charts can be found below:
* The bar in red indicates where J.Molner AS's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
J.Molner AS's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
J.Molner AS (OTSE:MOLNR) has a Enterprise Value of €32.40 Mil as of Sep. 01, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on J.Molner AS and its competitors.
Is J.Molner AS's Enterprise Value too high?
J.Molner AS's current Enterprise Value is €32.40 Mil. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's Enterprise Value compare to ZTS and UTHR?
J.Molner AS's Enterprise Value of €32.40 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on J.Molner AS and its competitors. J.Molner AS's current Enterprise Value is €32.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.63, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current Enterprise Value is €32.40 Mil. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current Enterprise Value is €32.40 Mil as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.63.
GuruFocus considers J.Molner AS to be Fairly Valued.
Key valuation signals for OTSE:MOLNR:
Enterprise Value: €32.40 Mil
GF Value™: €19.63 vs. price of €18.90 (3.7% below fair value)
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score
Get the complete analysis for OTSE:MOLNR
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
